Dimensional Fund Advisors LP Purchases 133,379 Shares of Astria Therapeutics, Inc. (NASDAQ:ATXS)

Dimensional Fund Advisors LP increased its position in Astria Therapeutics, Inc. (NASDAQ:ATXS) by 1,043.7% in the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 146,158 shares of the biotechnology company’s stock after purchasing an additional 133,379 shares during the quarter. Dimensional Fund Advisors LP’s holdings in Astria Therapeutics were worth $1,330,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds also recently made changes to their positions in the company. RA Capital Management L.P. bought a new stake in Astria Therapeutics during the first quarter worth about $62,115,000. Vanguard Group Inc. lifted its holdings in shares of Astria Therapeutics by 23.4% during the first quarter. Vanguard Group Inc. now owns 2,535,891 shares of the biotechnology company’s stock valued at $35,693,000 after purchasing an additional 480,184 shares during the last quarter. Artal Group S.A. bought a new stake in shares of Astria Therapeutics in the 1st quarter worth approximately $12,445,000. Bank of New York Mellon Corp grew its stake in shares of Astria Therapeutics by 6.9% in the 2nd quarter. Bank of New York Mellon Corp now owns 139,071 shares of the biotechnology company’s stock worth $1,266,000 after buying an additional 8,965 shares during the last quarter. Finally, Tidal Investments LLC purchased a new stake in shares of Astria Therapeutics in the 1st quarter worth approximately $1,664,000. 98.98% of the stock is currently owned by institutional investors.

Astria Therapeutics Trading Up 10.7 %

ATXS opened at $11.62 on Friday. Astria Therapeutics, Inc. has a 1-year low of $4.26 and a 1-year high of $16.90. The firm’s 50 day simple moving average is $11.29 and its two-hundred day simple moving average is $10.56. The company has a market capitalization of $638.09 million, a PE ratio of -5.01 and a beta of 0.71.

Astria Therapeutics (NASDAQ:ATXS) last announced its quarterly earnings data on Monday, August 12th. The biotechnology company reported ($0.43) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.05). Equities analysts forecast that Astria Therapeutics, Inc. will post -1.72 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several brokerages have recently weighed in on ATXS. Evercore ISI upgraded Astria Therapeutics to a “strong-buy” rating in a report on Wednesday, August 14th. HC Wainwright restated a “buy” rating and set a $16.00 price objective on shares of Astria Therapeutics in a research note on Friday, September 27th. Oppenheimer upped their target price on shares of Astria Therapeutics from $25.00 to $26.00 and gave the stock an “outperform” rating in a research note on Tuesday, August 13th. TD Cowen initiated coverage on shares of Astria Therapeutics in a research report on Monday, July 29th. They set a “buy” rating and a $35.00 price target for the company. Finally, Wedbush reaffirmed an “outperform” rating and issued a $22.00 price objective on shares of Astria Therapeutics in a research report on Tuesday, August 13th. Five research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Buy” and an average target price of $25.20.

Astria Therapeutics Company Profile

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.